Oxygen Biotherapeutics Mission & Goals

News & Events

Oxygen Biotherapeutics Announces Collaboration with Imperial College London to Accelerate Enrollment of LeoPARDS Trial

Company to support a 500+ patient study assessing benefit of levosimendan in septic shock patients

Wednesday, August 6, 2014 8:00 am EDT
Dateline:
MORRISVILLE, N.C.

Public Company Information:
NASDAQ:OXBT US69207P2092


MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced a collaboration with Imperial College London to provide supplemental funding to support the accelerated enrollment and completion of the ongoing LeoPARDS Trial (Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis) awarded by the Efficacy and Mechanism Evaluation (EME) Programme and funded by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership. Oxygen is also currently preparing to initiate a Phase 3 trial in the United States during the third quarter to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome (LCOS). more..

Quick Links

About Oxygen Biotherapeutics Mission

The Mission of Oxygen Biotherapeutics is to develop and market specialty pharmaceutical products that address unmet needs of critical care patients, their health care providers, and the hospitals who treat these patients.